NCT04776330View on ClinicalTrials.gov

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 7, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

July 1, 2027

Conditions
Multiple MyelomaNeoplasm, Plasma CellMultiple Myeloma in Relapse
Interventions
BIOLOGICAL

BCMA targeted prime CAR-T cells

BCMA targeted prime CAR-T cell therapy

Trial Locations (1)

Unknown

RECRUITING

920th Hospital of Joint Logistics Support Force, Kunming

All Listed Sponsors
lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY